December 17, 2024 | 11:00 am EST
Respiratory syncytial virus (RSV) is the leading cause of pneumonia and bronchiolitis in infants, as well as hospitalisations and deaths in the first months of life. Currently, there are no specific treatments for RSV infection, making supportive measures the main line of therapy. Among the preventive measures, maternal vaccination aims to prevent RSV-associated disease in infants during the first six months through the transfer of antibodies during gestation. The PAHO Technical Advisory Group has issued recommendations on the use of this vaccine in the Americas, and PAHO has published an annex to the Field Guide on Maternal and Neonatal Immunisation for Latin America and the Caribbean, specific to maternal RSV vaccination.
Objective:
To disseminate relevant information on the maternal RSV vaccine based on prefusion protein F (RSVpreF) for the prevention of RSV-associated complications in infants, including the annex to the Field Guide, PAHO Advisory Group recommendations and considerations for implementation.
Target audience
Representatives from national and sub-national Ministries of Health, immunisation, maternal and newborn health programme managers, health facility and programme managers, non-governmental organisations, professional associations with expertise in maternal and newborn care, health professionals involved in antenatal care, researchers, community representatives and users.
AGENDA
Duration | Session | Speaker |
| 5 minutes | Welcome | Suzanne Serruya (PAHO/HSS) |
| 15 minutes | Introduction to the Field Guide on Maternal and Neonatal Immunisation for Latin America and the Caribbean and the Annex on Maternal Respiratory Syncytial Virus Vaccination | Bremen De Mucio (PAHO/HSS) |
| 10 minutes | Respiratory syncytial virus disease and prevention measures | Francisco Nogareda (PAHO/CIM) |
| 10 minutes | Maternal RSVPreF vaccine: efficacy and safety | Danny Feikin (WHO) |
| 10 minutes | PAHO and SAGE Technical Advisory Group Recommendations | Margherita Ghiselli (PAHO/CIM) |
| 15 minutes | Implementation considerations. Argentina's experience | María del Valle Juárez (DICEI Argentina) |
| 20 minutes | Questions and answers | Bremen De Mucio (PAHO/HSS) |
| 5 minutes | Conclusions and closure | Martha Velandia (PAHO/CIM) |
Simultaneous interpretation will be provided in Spanish and English.
If you have doubts about the time in your country you can select this link.